James W. Wells

Reprogramming tumour-associated macrophages from immune suppressive to inflammatory state by Checkpoint kinase 1 inhibitor combination treatment

This study shows that CHK1i+LDHU reprograms tumour-associated macrophages to an inflammatory state while preserving immunosuppressive features, enhancing CD8 T cell activation and therapeutic efficacy.

Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer

This study evaluates CHK1i+LDHU therapy in HGSOC, showing it kills cancer cells and reprograms the tumor microenvironment to enhance anti-tumor immune responses.